Abbott Laboratories (ABT) Share-based Compensation (2009 - 2026)

Abbott Laboratories has disclosed Share-based Compensation across 18 years of filings, most recently posting $168.0 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 18.31% year-over-year to $168.0 million; the TTM figure through Jun 2026 stood at $718.0 million (up 8.95% YoY), while the FY2025 annual figure was $664.0 million, down 1.34% from the prior year.
• Share-based Compensation came in at $168.0 million for Q2 2026 at Abbott Laboratories, down from $317.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $317.0 million in Q1 2026 to a low of $111.0 million in Q4 2024.
• Average Share-based Compensation over 5 years is $175.1 million, with a median of $136.5 million recorded in 2023.
• Year-over-year, Share-based Compensation tumbled 77.98% in 2022 and advanced 18.31% in 2026.
• Over 5 years, Share-based Compensation stood at $115.0 million in 2022, then slipped by 0.87% to $114.0 million in 2023, then dropped by 2.63% to $111.0 million in 2024, then climbed by 1.8% to $113.0 million in 2025, then surged by 48.67% to $168.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $168.0 million in Q2 2026, $317.0 million in Q1 2026, and $113.0 million in Q4 2025.